Creating a new topical treatment for fungal nail infections
Development and optimization of a nitric oxide releasing microparticle-basedtopical treatment for onychomycosis
This study is testing a new skin treatment that uses tiny particles to deliver nitric oxide directly to fungal nail infections, which could help people with onychomycosis feel better and avoid the side effects of traditional antifungal medicines.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Zylo Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Greenville, United States) |
| Project ID | NIH-10686200 on NIH RePORTER |
What this research studies
This research focuses on developing a novel microparticle-based topical treatment that releases nitric oxide to effectively combat onychomycosis, a challenging fungal nail infection. The approach aims to enhance drug delivery through the nail plate, overcoming the limitations of current antifungal treatments. By utilizing a targeted delivery system, the research seeks to improve cure rates and reduce the side effects associated with systemic antifungal medications. Patients with onychomycosis may experience significant improvements in their condition and overall quality of life if this treatment proves successful.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with onychomycosis, particularly those who have not responded well to existing treatments.
Not a fit: Patients with nail infections caused by non-fungal pathogens or those who do not have onychomycosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer treatment option for patients suffering from onychomycosis.
How similar studies have performed: While there have been various approaches to treating onychomycosis, the specific use of nitric oxide releasing microparticles is a novel strategy that has not been extensively tested in this context.
Where this research is happening
Greenville, United States
- Zylo Therapeutics, INC. — Greenville, United States (Active)
Researchers
- Principal investigator: Draganski, Andrew R — Zylo Therapeutics, INC.
- Study coordinator: Draganski, Andrew R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.